button bars forest bayes pooled summary circles
 
DCR

mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative

versus durvalumab alone
durvalumab plus tremelimumab vs. durvalumab alone 1 certainty unassessable-41%
versus tremelimumab
durvalumab plus tremelimumab vs. tremelimumab 1 certainty unassessable+841%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons